By Kiran Mazumdar Shaw The Finance Minister has presented a comprehensive and wide-ranging Budget for FY19, which addresses most of the areas that need focus to ensure sustainable, long-term and equitable growth of the Indian economy. The Union Budget needed to be prudent and forward-looking rather than populist and that is exactly what Finance Minister … Continue reading An Inclusive Budget
There are nearly half a billion diabetes patients in the world. The alarming growth in the global diabetes population is leading to a huge demand for effective therapies from pre/early diabetes to late-stage disease. Of the 100 million people who need insulin globally, however, only ‘one in two’ can manage and afford costs associated with … Continue reading Biocon Advances In War Against Diabetes
When you can’t tax the rich, tax the less well-off. This is exactly what the Karnataka government did by notifying all hospitals to collect 8% luxury tax from every patient in an intensive care unit (ICU). Lying on an ICU bed fighting for one’s life is not a luxury by any stretch. But the room … Continue reading Can healthcare costs in India come down further?
In today’s world, technology is playing a transformational role in enabling innovation and driving change. New ideas, new business models and new technologies are leading to the birth of the “ideas economy,” where the “innovation quotient” has emerged as the key determinant of market value. India will lose out on the opportunity to benefit from innovation-led, … Continue reading IP Creation Can Make India the Next Global Innovation Hub
The fiscal year gone by has been one of the most exciting ones for Biocon. We delivered on our promise of affordable innovation, recorded robust top line and bottom line growth, augmented our capacities, optimized our product portfolio and introduced initiatives to achieve operational efficiencies. We successfully commercialized two world-class, low-cost monoclonal antibodies, an outcome … Continue reading Why FY14 was a Remarkable Year for Biocon
Over the last few days, media has been abuzz with the news of Sun Pharma’s $4-billion acquisition of Ranbaxy. Given the fact that it is the second largest acquisition in the Indian pharmaceutical sector till date, it is not surprising that everybody is fixated on the sheer size of the deal. But if you look … Continue reading Sun Pharma-Ranbaxy Deal Has Some Important Lessons
Global Impact of India’s Pharma Industry Imagine a scenario where a life-saving medicine for HIV/AIDS costs $12,000 a year, pushing it out of reach for most patients who need it. Or a world where a rotavirus vaccine costs $9 per dose, making it too expensive for most children across the globe. Now, consider a reality where … Continue reading Indian Pharma: Regaining Our Brand Equity